Analysis of peripheral blood of 59 metastatic melanoma patients showed increased levels of MDSCs and their chemoattractant factors in patients poorly responsive or resistant to treatment with the CTLA-4 inhibitor. Here, CTLA4 is linked to metastatic melanoma.